- Home
- HSTM vs JANX Comparison
HSTM vs JANX Comparison
Compare HSTM & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HSTM | JANX |
|---|---|---|
| Founded | 1990 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 882.7M | 1.0B |
| IPO Year | 1999 | 2021 |
Fundamental Metrics
Financial Performance| Metric | HSTM | JANX |
|---|---|---|
| Price | $28.96 | $12.43 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 18 |
| Target Price | ★ $36.00 | $32.47 |
| AVG Volume (30 Days) | 206.9K | ★ 930.1K |
| Earning Date | 11-02-2026 | 11-05-2026 |
| Dividend Yield | ★ 0.49% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.61 | N/A |
| Revenue | ★ $304,064,000.00 | $10,000,000.00 |
| Revenue This Year | $9.19 | $188.72 |
| Revenue Next Year | $4.38 | N/A |
| P/E Ratio | $47.41 | ★ N/A |
| Revenue Growth | ★ 4.26 | N/A |
| 52 Week Low | $19.50 | $11.59 |
| 52 Week High | $35.61 | $35.34 |
Technical Indicators
Market Signals| Indicator | HSTM | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 34.43 | 30.92 |
| Support Level | $27.77 | N/A |
| Resistance Level | $30.21 | $14.47 |
| Average True Range (ATR) | 1.59 | 1.34 |
| MACD | -0.74 | -0.60 |
| Stochastic Oscillator | 12.89 | 9.52 |
Price Performance
Historical ComparisonAbout HSTM HealthStream Inc.
HealthStream Inc provides SaaS based applications for healthcare organizations all designed to improve business and clinical outcomes by supporting the people who deliver patient care. The company is focused on helping individuals and organizations in healthcare meet their ongoing learning, clinical development, credentialing, and scheduling needs. It also provides its solutions to nursing schools and nursing students.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.